BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 9094456)

  • 1. Extracorporeal photochemotherapy induces a significant increase in CD36+ circulating monocytes in patients with mycosis fungoides.
    Fimiani M; Rubegni P; Pimpinelli N; Mori M; De Aloe G; Andreassi L
    Dermatology; 1997; 194(2):107-10. PubMed ID: 9094456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and Sézary Syndrome.
    Zic JA
    Dermatol Clin; 2015 Oct; 33(4):765-76. PubMed ID: 26433848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extracorporeal photochemotherapy induces apoptosis of infiltrating lymphoid cells in patients with mycosis fungoides in early stages. A quantitative histological study.
    Miracco C; Rubegni P; De Aloe G; D'Ascenzo G; Mazzatenta C; De Santi MM; Fimiani M
    Br J Dermatol; 1997 Oct; 137(4):549-57. PubMed ID: 9390330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extracorporeal photopheresis for the treatment of erythrodermic cutaneous T-cell lymphoma: a single center clinical experience with long-term follow-up data and a brief overview of the literature.
    Quaglino P; Knobler R; Fierro MT; Savoia P; Marra E; Fava P; Bernengo MG
    Int J Dermatol; 2013 Nov; 52(11):1308-18. PubMed ID: 23786842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: a prospective controlled trial.
    Wollina U; Looks A; Meyer J; Knopf B; Koch HJ; Liebold K; Hipler UC
    J Am Acad Dermatol; 2001 Feb; 44(2):253-60. PubMed ID: 11174383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of advanced mycosis fungoides/Sézary syndrome with fludarabine and potential adjunctive benefit to subsequent extracorporeal photochemotherapy.
    Quaglino P; Fierro MT; Rossotto GL; Savoia P; Bernengo MG
    Br J Dermatol; 2004 Feb; 150(2):327-36. PubMed ID: 14996105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of apoptosis markers on peripheral blood lymphocytes from patients with cutaneous T-cell lymphoma during extracorporeal photochemotherapy.
    Osella-Abate S; Zaccagna A; Savoia P; Quaglino P; Salomone B; Bernengo MG
    J Am Acad Dermatol; 2001 Jan; 44(1):40-7. PubMed ID: 11148475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of the cutaneous peripheral T-cell lymphomas: when subtypes matter.
    Choi MY; Lechowicz MJ
    Cancer J; 2012; 18(5):439-44. PubMed ID: 23006949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of cutaneous T-cell lymphomas (CTCL) with extracorporeal photochemotherapy--preliminary report.
    Nagatani T; Matsuzaki T; Kim S; Baba N; Osawa J; Sugiyama A; Komatsu H; Ichiyama S; Takahashi Y; Miyamoto H
    J Dermatol; 1990 Dec; 17(12):737-45. PubMed ID: 2086618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized cross-over study to compare PUVA and extracorporeal photopheresis in the treatment of plaque stage (T2) mycosis fungoides.
    Child FJ; Mitchell TJ; Whittaker SJ; Scarisbrick JJ; Seed PT; Russell-Jones R
    Clin Exp Dermatol; 2004 May; 29(3):231-6. PubMed ID: 15115499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma.
    Duvic M; Chiao N; Talpur R
    J Cutan Med Surg; 2003; 7(4 Suppl):3-7. PubMed ID: 12958700
    [No Abstract]   [Full Text] [Related]  

  • 14. Tumor microenvironment in mycosis fungoides and Sézary syndrome.
    Rubio Gonzalez B; Zain J; Rosen ST; Querfeld C
    Curr Opin Oncol; 2016 Jan; 28(1):88-96. PubMed ID: 26632770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Extracorporeal photopheresis in the therapy of Sézary syndrome].
    Marschalkó M; Knobler R; Soós G; Berecz M; Pálóczy K; Rácz I
    Orv Hetil; 1993 Jun; 134(23):1253-7. PubMed ID: 8332344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Photopheresis therapy for cutaneous T-cell lymphoma.
    Duvic M; Hester JP; Lemak NA
    J Am Acad Dermatol; 1996 Oct; 35(4):573-9. PubMed ID: 8859287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of extracorporeal photopheresis alone or in combination therapy on circulating CD4(+) Foxp3(+) CD25(-) T cells in patients with leukemic cutaneous T-cell lymphoma.
    Shiue LH; Couturier J; Lewis DE; Wei C; Ni X; Duvic M
    Photodermatol Photoimmunol Photomed; 2015 Jul; 31(4):184-94. PubMed ID: 25772268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What Does the Future Hold for Biomarkers of Response to Extracorporeal Photopheresis for Mycosis Fungoides and Sézary Syndrome?
    Akilov OE
    Cells; 2023 Sep; 12(18):. PubMed ID: 37759543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic reduction of cell-mediated immunosuppression in mycosis fungoides and Sézary syndrome.
    Geskin LJ; Akilov OE; Kwon S; Schowalter M; Watkins S; Whiteside TL; Butterfield LH; Falo LD
    Cancer Immunol Immunother; 2018 Mar; 67(3):423-434. PubMed ID: 29204699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD30
    Ellis A; Christensen LF; Sharma T; Meyerson H; Kord H; Cooper KD
    J Am Acad Dermatol; 2021 Feb; 84(2):530-532. PubMed ID: 32437721
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.